High IgG levels at diagnosis tied to worse PBC outcomes: Study
High blood levels of the antibody immunoglobulin G, or IgG, at diagnosis are linked to a more severe disease course among people with primary…
News
AI model may predict cholestasis-related cognitive impairment risk
An artificial intelligence (AI) model can accurately discriminate between cholestasis patients with and without moderate to severe disease-associated cognitive impairment based on 13 possible…
American Liver Foundation gears up for advocacy summit
Patients, caregivers, and supporters will head to Washington later this month to advocate for policies to improve life for people living with fatty liver…
New AI model helps make accurate diagnoses of biliary atresia
A new artificial intelligence (AI) model based on clinical data along with laboratory results and ultrasound images aids the early diagnosis of biliary atresia,…
FDA grants fast track status to gene-editing therapy for hepatitis B
The U.S. Food and Drug Administration (FDA) has granted fast track status to PBGENE-HBV, Precision Bioscience’s gene-editing therapy candidate for chronic hepatitis B…
Focus of World Liver Day this April 19 is role of diet in liver health
Supporters are gearing up for World Liver Day on April 19 — marked by a global campaign to raise awareness about liver health and…
FDA approves Livmarli oral tablets for PFIC, Alagille
The U.S. Food and Drug Administration (FDA) has approved an oral tablet formulation of Livmarli (maralixibat) to treat progressive familial intrahepatic cholestasis (PFIC)…
GLP-1 agonists linked to lower risk of complications in MASLD, MASH
Use of glucagon-like peptide-1 (GLP-1) receptor agonists in people with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH) — forms of…
COVID-19 complicates vascular problems in woman with Alagille
A 34-year-old woman with Alagille syndrome and vascular problems — who had been implanted with a stent for her narrowed pulmonary arteries — experienced…
First patient dosed in Phase 3 trial of hepatitis C combination therapy
The first participant has been dosed in a Phase 3 clinical trial testing Atea Pharmaceuticals’ combination therapy bemnifosbuvir and ruzasvir in adults with chronic…
